Completed PHASE1/PHASE2 INTERVENTIONAL NCT00734396

Mesenchymal Stem Cells and Subclinical Rejection (Measure)

Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Allograft Rejection After Renal Transplantation

Sponsor: Leiden University Medical Center

Interventions Mesenchymal stem cell infusion

Updated 5 times since 2017 Last updated: Jan 4, 2013 Started: Feb 28, 2009 Primary completion: Mar 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00734396, this PHASE1/PHASE2 trial focuses on Organ Transplantation and remains completed. Sponsored by Leiden University Medical Center, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Leiden University Medical Center

Data source: Leiden University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leiden, Netherlands